Table 3.
Average BL CTV values for five non-perturbed cases.
| CTV | Parameters |
|---|---|
| CTV1_PLNs | |
| D98% (Gy(RBE)) | 45.42 ± 0.10 |
| V45Gy(RBE) (%) | 99.82 ± 0.18 |
| D2% (Gy(RBE)) | 46.64 ± 0.17 |
| HI2–98% | 0.03 ± 0.00 |
| CTV1_Pro+SVs | |
| D98% (Gy(RBE)) | 45.40 ± 0.13 |
| V45Gy(RBE) (%) | 99.99 ± 0.03 |
| D2% (Gy(RBE)) | 46.44 ± 0.17 |
| HI2–98% | 0.02 ± 0.00 |
| CTV2_Pro+proxSVs | |
| D98% (Gy(RBE)) | 34.45 ± 0.14 |
| V45Gy(RBE) (%) | 99.87 ± 0.25 |
| D2% (Gy(RBE)) | 35.21 ± 0.24 |
| HI2–98% | 0.02 ± 0.01 |
CTV, clinical target volume; Gy(RBE); gray(radiobiological equivalent); Dx, dose received by target at a defined volume (x) in percentage; Vx, volume of target receiving a defined dose (x) in Gray; HI, homogeneity index; PLNs, pelvic lymph nodes; Pro + SVs, prostate and seminal vesicles; Pro + proxSVs, prostate and proximal seminal vesicles; *p < 0.05, statistically significant.